GlassScriptPhysician profile
Frank P Cricchio
NPI 1851307185
$3,809.48
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,336 · 2020: $1,033 · 2021: $1,066 · 2022: $38.05 · 2023: $206 · 2024: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $336.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $284.94 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $277.94 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $273.22 | 2019-2021 | |
| Novo Nordisk INC | $234.79 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.45 | 2019-2023 | Cyltezo |
| Pfizer INC. | $201.31 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $197.34 | 2019-2021 | |
| Glaxosmithkline, LLC. | $195.01 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $186.02 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $180.81 | 2019-2022 | |
| Eisai INC. | $155.09 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $137.10 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $127.30 | 2019-2021 | |
| Genzyme Corporation | $124.72 | 2023-2024 | |
| Antares Pharma, INC. | $113.94 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $99.16 | 2019-2021 | |
| Allergan, INC. | $94.47 | 2019-2020 | |
| Abbvie INC. | $76.99 | 2021 | |
| Incyte Corporation | $59.30 | 2023-2024 | Opzelura |
| Genentech USA, INC. | $55.32 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $53.22 | 2019 | |
| Sun Pharmaceutical Industries INC. | $46.17 | 2023 | Ilumya, Blu-U, Odomzo |
| Bausch Health US, LLC | $43.45 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $38.74 | 2023-2024 | Jublia, Arazlo, Duobrii |
| Teva Pharmaceuticals USA, INC. | $35.97 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.23 | 2019-2021 | |
| Orexo US, INC. | $31.98 | 2019 | |
| Novartis Pharmaceuticals Corporation | $31.43 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $29.81 | 2019-2020 | |
| Horizon Therapeutics Plc | $28.01 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $24.10 | 2023 | Dupixent |
| Biofrontera INC. | $21.27 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Sanofi-Aventis U.S. LLC | $20.71 | 2020 | |
| Amgen INC. | $16.95 | 2021 | |
| Indivior INC. | $16.74 | 2021 | |
| Concordia Pharmaceuticals INC. | $15.13 | 2019 | |
| Aytu Biopharma, INC. | $14.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Cricchio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.